Biosimilars

September 2nd 2025

The FDA approves denosumab-nxxp (Bildyos and Bilprevda), enhancing access to vital bone health treatments for osteoporosis and cancer-related conditions.

May 28th 2025

This designation follows Hadlima’s low-concentration prefilled syringes and single-dose vials, which were designated in June 2024.

May 27th 2025

Ustekinumab is a medication used to treat and manage inflammatory conditions, including psoriasis, psoriatic arthritis, and inflammatory bowel disease.

May 23rd 2025

Adalimumab-aaty (Yuflyma) prefilled syringes and autoinjectors are now fully interchangeable with the reference product adalimumab (Humira) across marketed dosage forms and strengths.